Midatech Pharma (MTPH)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 20.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 160.00p
  • 52 Week Low: 16.50p
  • Currency: UK Pounds
  • Shares Issued: 32.59m
  • Volume: 2,166
  • Market Cap: £6.52m
  • RiskGrade: 707

Midatech Pharma doses first volunteers in acromegaly treatment study

By Duncan Ferris

Date: Tuesday 08 Oct 2019

LONDON (ShareCast) - (Sharecast News) - Midatech Pharma on Tuesday announced that its MTD201 Phase 1 study for the treatment of acromegaly and neuroendocrine tumours has commenced.
Half of the trial's 28 healthy volunteers were injected with a dose of Sandostatin 100 microgram/1 ml solution on 5 October before receiving a 30mg injection of MTD201 on Monday.

The remaining subjects will undergo the same procedures later this week to complete the dosing phase. Volunteers will then begin a 63-day observation and sampling period, after which the company said it expected data to be analysed and results released in late 2019 or early next year.

Acromegaly is a hormonal disorder that results in abnormal growth of bones, particularly in the hands, feet and face, while neuroendocrine tumours can also result in the production of excess hormones.

Midatech in September said the objective of the newly launched trial is to determine the administration route for a pivotal registration study to be commenced in 2020.

The company has previously tested MTD201 in a 2018 phase 1 exploratory study, after which it said the treatment had delivered favourably when compared to the market-leading alternative, Sandostatin LAR, with advantages including smaller needle sizes, simpler injection and quicker bedside reconstitution.

Midatech Pharma shares were up 2.20% at 6.26p at 1026 BST.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

MTPH Market Data

Currency UK Pounds
Share Price 20.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 160.00p
52 Week Low 16.50p
Volume 2,166
Shares Issued 32.59m
Market Cap £6.52m
RiskGrade 707

MTPH Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
32.87% above the market average32.87% above the market average32.87% above the market average32.87% above the market average32.87% above the market average
45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average
Price Trend
98.01% below the market average98.01% below the market average98.01% below the market average98.01% below the market average98.01% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Income Not Available
Growth
36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average

MTPH Dividends

No dividends found

Trades for 13-Jul-2020

Time Volume / Share Price
08:42 1,228 @ 19.55p
08:12 926 @ 20.30p
08:05 12 @ 19.55p

Top of Page